Pleural Irrigation with a Novel Device for Pleural Effusion

This study is testing a new way to treat retained pleural effusion (fluid buildup around the lungs) using a device called the CLR™ irrigator. This device helps deliver saline (saltwater) directly into the chest cavity. You might be able to join if you have retained pleural effusion after a chest tube insertion and cannot receive standard enzyme therapy. The researchers want to see if this irrigation method can reduce the amount of fluid around your lungs, measured daily by ultrasound for 8 days. The study plans to enroll 10 participants, but its current status is unclear.

Study design
This is a single-arm pilot study, meaning all 10 participants will receive the same intervention. It is designed to test the use of intrapleural saline irrigation.
What's involved
Participants will have a CLR™ port and CLR™ irrigator added to their chest tube and atrium circuit. Radiographic improvement will be measured daily by bedside ultrasound for 8 days.
Compensation
Not stated in the trial record.
Follow-up
Radiographic improvement will be measured daily for 8 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06727578

Pleural Irrigation With a Novel Devise.

Recruiting
NAAges 18+InterventionalTreatment
Beth Israel Deaconess Medical Center
~10 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:of intrapleural saline irrigation with CLR irrigator

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Radiographic improvement (reduction in the ammount of pleural effusion messured in centimeters) by bed side ultrasound day 1,2,3,4,5.
Measured over Daily for 8 days
Pleural Effusion Disorder
1 sites across 1 states
Massachusetts1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Retained pleural effusion identified via bedside ultrasound within the first 24 hours after chest tube insertion
Patient is contraindicated from receiving intrapleural enzymatic therapy within the first 24 hours after chest tube insertion

Exclusion

Non-infectious cause of pleural fluid analysis findings listed above identified (e.g. malignancy)
Post-procedural empyema or complicated parapneumonic effusion
  • Radiographic improvement (reduction in the ammount of pleural effusion messured in centimeters) by bed side ultrasound day 1,2,3,4,5.Daily for 8 days